Science 37 facilitated significant U.S. enrollment in a Phase 3 trial for cholestatic pruritus, enhancing patient access through remote participation.Quiver AI SummaryScience 37, a leader in improving...
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial...
OpenSesame today announced it has appointed Tamar Elkeles, PhD, and Emily Rollins to its Board of Directors. Dr. Elkeles is a highly regarded Chief Human Resources Officer and thought leader, advising...
RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™...
Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months...
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™,...
RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™,...
New offering provides access to patients beyond the existing site network can be implemented in four weeks....
New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying stakeholder journeys, increasing...